- Home
- SPHL vs AIDX Comparison
SPHL vs AIDX Comparison
Compare SPHL & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHL | AIDX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.7M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SPHL | AIDX |
|---|---|---|
| Price | $2.74 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.3K | ★ 85.6K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,045,133.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.35 | $0.40 |
| 52 Week High | $25.11 | $14.09 |
Technical Indicators
Market Signals| Indicator | SPHL | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 54.59 |
| Support Level | $2.48 | $0.52 |
| Resistance Level | $2.74 | $0.57 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 24.29 | 92.17 |
Price Performance
Historical ComparisonAbout SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.